Quickgene
SFDA · Regulatory

Characterization Requirements for Generic Synthetic Peptides in Saudi Arabia: SFDA Guideline DS-G-143 and the GCC Dossier

By QuickgenePublished Approx. 8 min read

Abstract

Saudi Arabia now has a dedicated quality guideline for synthetic peptides. SFDA guideline DS-G-143-V01 was issued on 29 September 2026 and took effect on 29 October 2026. It splits generic peptides into two cases. If the reference product is itself chemically synthesized, the focus is a comparable impurity profile. If the reference product is of biological origin, the biosimilar pathway is not available; the applicant instead needs side-by-side analytical comparability on a broad panel, ideally on at least 10 commercial batches, including aggregate size and level, peptide-related impurities at the same level or lower, comparative forced degradation and in-silico immunogenicity prediction. This page summarizes what the guideline asks for, which methods it names, and where it leaves the choice of method to the applicant.

Keywords: SFDA; Saudi Arabia; GCC; synthetic peptides; generic peptides; semaglutide; analytical comparability; aggregation; immunogenicity; DS-G-143

1 Why this matters now

Demand for generic GLP-1 peptides in Saudi Arabia is no longer theoretical. Hikma launched Glucentra, described by the company as the first generic semaglutide in the Kingdom, on 16 September 2026, after its manufacturing partner OneSource received SFDA approval earlier in the year. Two weeks later SFDA issued its first guideline written specifically for the quality of synthetic peptides.

For companies preparing Saudi or GCC filings, the practical question is which analytical evidence the reviewer will expect. The sections below answer that from the SFDA documents themselves.

2 The documents that apply

Saudi Arabia · SFDA

Guideline on the Quality of Synthetic Peptides, DS-G-143-V01

Issued / in force
Issued 29 Sep 2026; in force 29 Oct 2026
Scope
Development, manufacture, characterization, specifications and analytical procedures for synthetic peptides for human use. Excludes peptides from biological sources and radiopharmaceuticals
Key point
Generic peptides with a biological reference cannot use the biosimilar pathway

Saudi Arabia · SFDA

Data Requirements for Human Drugs Submission, DS-REQ-002 version 4.0

Updated
Version 4.0, August 2025
Format
CTD Modules 1–5 in eCTD; generics generally do not need Module 4
New in v4.0
Mandatory nitrosamine risk assessment; calculation formulas and raw data for analytical procedures

Saudi Arabia · SFDA

General Guideline on Requirements for Development and Approval of Biosimilars, DS-G-138-V01

Issued / in force
Issued 10 Jun 2026; in force 10 Jul 2026
Relevance
States that synthetic peptides are excluded from its scope

GCC

GCC dossier format and stability guidelines

Dossier
SFDA data requirements use the GCC CTD structure and GCC Module 1
Stability
SFDA refers applicants to the GCC stability guidelines for drug substances and drug products

3 First decide which case your product falls into

Section 2.3 of DS-G-143 treats generic peptides differently depending on the reference product. Classify the reference product before planning any study.

Case A: chemically synthesized reference (section 2.3.1). The main concern is a difference in purity profile. Similar impurity profiles are expected because the synthetic routes are usually similar. Peptide-related impurities should be shown to be comparable under long-term and accelerated storage, and the reference product's limits, including aggregation limits, may be applied.
Case B: biological reference product (section 2.3.2). SFDA states that the biosimilar pathway is not possible for chemically synthesized peptides. Instead, the applicant submits side-by-side physicochemical and analytical comparability data in section 3.2.S.3. Liraglutide and semaglutide are examples where the originator product is made by recombinant DNA technology, so a synthetic generic of either falls in this case.

4 Case B in detail: what the comparability package must contain

  • Reference product source: the Saudi market, or markets regulated by reputable regulatory authorities.
  • Number of batches: SFDA recommends at least 10 commercial batches for the side-by-side analysis, or a justified number.
  • Aggregates: compare aggregate size and level profiles; SFDA notes this comparison may address immunogenicity concerns.
  • Peptide-related impurities: at the same level or lower in the synthetic product than in the reference.
  • Forced degradation: comparative forced-degradation studies are recommended.
  • Immunogenicity: in-silico prediction of immunogenic impurities arising from synthesis or degradation, where applicable.
  • Methods: qualified, validated and sufficiently sensitive. The extent of comparative non-clinical and clinical work depends on the outcome of the analytical comparison.

5 Characterization methods named by the guideline, and how they map to testing

Table 1 of DS-G-143 lists characterization methods by structural level; Table 3 lists example specification tests. The cards below follow that structure. Where the guideline does not name a method we use, we say so.

  1. Primary structure and identity

    Table 1Table 3
    What SFDA asks for
    Primary structure for every synthetic peptide; at least two independent identification tests at release.
    Methods named in DS-G-143
    Peptide mapping with MS, Edman sequencing, amino acid analysis, MS-MS, RP-HPLC, NMR

    Quickgene provides

    Amino acid analysis and supporting characterization; see the AAA technical article

  2. Secondary and tertiary structure

    Table 1
    What SFDA asks for
    Higher-order structure as applicable; case by case for complex and cyclic peptides.
    Methods named in DS-G-143
    Far-UV CD, FTIR, Raman, NMR, fluorescence; near-UV CD, intrinsic fluorescence, DSC, disulfide analysis

    Quickgene provides

    Far- and near-UV circular dichroism with side-by-side comparison against the reference

  3. Aggregation and self-association

    Table 1Table 32.3.2
    What SFDA asks for
    Aggregate size and level compared with the reference; aggregation in the specification.
    Methods named in DS-G-143
    SEC-UV, SEC-MALS, CG-MALS, Thioflavin T

    Quickgene provides

    SEC with orthogonal confirmation by SV-AUC. SV-AUC is not named in DS-G-143; we propose it as an orthogonal method because it measures self-association without a column

  4. Biological activity

    Table 1Table 3
    What SFDA asks for
    Biological activity by cell-based or other assays; bio-identity can be considered for complex and long peptides.
    Methods named in DS-G-143
    Cell-based and other biological assays
  5. Peptide-related impurities

    2.1.2.42.3.2
    What SFDA asks for
    Impurities identified and controlled; same level or lower than the reference in Case B.
    Methods named in DS-G-143
    LC-HRMS or LC-MS/MS; orthogonal separations such as RP-HPLC and ion exchange

    Quickgene provides

    Impurity reference standards for semaglutide, tirzepatide, retatrutide and cagrilintide

  6. Charge heterogeneity

    Not named
    What SFDA asks for
    DS-G-143 lists deamidation and racemization among degradation impurities but names no charge-based method.
    Methods named in DS-G-143
    Not specified

    Quickgene provides

    icIEF charge profiles as supporting characterization, where the applicant chooses to include them

6 Other dossier requirements to plan for

  • Nitrosamine risk assessment for drug substance and drug product is mandatory under the SFDA data requirements (DS-REQ-002, version 4.0).
  • Extractables and leachables from the container-closure system must be submitted for peptide drug products (DS-G-143, section 2.3).
  • Analytical validation follows ICH Q2; DS-G-143 also refers to ICH Q14 for analytical development. In-house methods need full validation with representative chromatograms.
  • Stability follows ICH Q1 and the SFDA/GCC stability guidance, with specific data on degradation, aggregation, water content and pH where relevant.
  • Counter-ion content (acetate, chloride or trifluoroacetate) is a specification item because it can affect secondary structure and activity.

7 What the guideline does not specify

DS-G-143 gives no numeric reporting, identification or qualification thresholds for peptide-related impurities. It requires thresholds to be justified by toxicological, clinical or other relevant data, and refers non-peptide impurities to ICH Q3A–Q3D and M7. It also does not name analytical ultracentrifugation or capillary isoelectric focusing. Applicants therefore choose and justify their own orthogonal methods; the sensible reference points are the EMA synthetic-peptide guideline and the reference product's own data.

Egypt has a separate route. The Egyptian Drug Authority publishes a regulatory guide for synthetic peptides that refer to a reference peptide of rDNA origin, applicable to products manufactured locally in Egypt. It is a different document with different procedures from the SFDA guideline.

References

Primary (SFDA and other regulators)

  1. Saudi Food and Drug Authority. (2026). Guideline on the Quality of Synthetic Peptides, DS-G-143-V01/260929. Issued 29 September 2026; implemented 29 October 2026. https://www.sfda.gov.sa/sites/default/files/2026-09/Quality%20REQs%20for%20synthetic%20peptides_GV01.pdf
  2. Saudi Food and Drug Authority. (2025). Data Requirements for Human Drugs Submission – Content of the Dossier, DS-REQ-002, Version 4.0. https://www.sfda.gov.sa/sites/default/files/2026-04/Data-Human-Drugs-SubV4.pdf
  3. Saudi Food and Drug Authority. (2026). General Guideline on Regulatory and Scientific Requirements for Development and Approval of Biosimilars, DS-G-138-V01/260510. https://www.sfda.gov.sa/sites/default/files/2026-06/GGRSRBA.pdf
  4. Egyptian Drug Authority. Regulatory Guide on the Registration of Synthetic Peptides Human Pharmaceutical Products that Refer to a Reference Peptide Product of rDNA Origin. https://edaegypt.gov.eg/media/e0bdqwph/guide-line-synthetic-peptide-regulatory-v-4.pdf

Secondary (market context)

  1. Hikma Pharmaceuticals. (2026, 16 September). Hikma launches Glucentra as the first generic semaglutide available to patients in Saudi Arabia. https://www.hikma.com/news/hikma-launches-glucentra-as-the-first-generic-semaglutide-available-to-patients-in-saudi-arabia/